Motifene (Diclofenac Sodium)

Diclofenac Sodium, the active ingredient in Motifene, is a nonsteroidal anti-inflammatory drug (NSAID) presented as an oral dosage form for oral use. It is employed to relieve pain and reduce inflammation in conditions such as osteoarthritis, rheumatoid arthritis and other musculoskeletal disorders.

GNH USA supplies Motifene as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Diclofenac Sodium is an NSAID that acts on inflammatory pathways to manage several painful and inflammatory conditions.

- Osteoarthritis: reduces joint pain and swelling, improving mobility. - Rheumatoid arthritis: alleviates chronic joint inflammation and discomfort. - Musculoskeletal pain: provides rapid relief of strain, sprain and back pain. - Acute pain: diminishes short‑term pain following injury or surgery.

Adverse reactions may range from mild to severe, depending on individual susceptibility and duration of therapy.

Common Side Effects: - Gastrointestinal upset: nausea, dyspepsia or abdominal discomfort. - Headache: mild to moderate intensity. - Dizziness or vertigo. - Skin rash or pruritus. - Elevated liver enzymes.

Serious or Rare Side Effects: - Gastrointestinal bleeding or ulcer perforation. - Severe hepatic injury or jaundice. - Acute renal failure or significant decline in kidney function. - Life‑threatening skin reactions such as Stevens‑Johnson syndrome. - Anaphylactic or severe allergic reactions.

Before initiating therapy, consider the following safety measures.

- Assess renal function: adjust use in patients with impaired kidney function. - Monitor hepatic enzymes: exercise caution in liver disease. - Avoid in active peptic ulcer disease: heightened risk of gastrointestinal bleeding. - Use with caution when combined with anticoagulants: increased bleeding potential. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Diclofenac may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased risk of serious bleeding. - Selective COX‑2 inhibitors: additive gastrointestinal and cardiovascular toxicity. - Lithium: potential rise in serum lithium concentrations.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: possible reduction in renal function. - Diuretics: may diminish renal clearance and increase nephrotoxicity. - Methotrexate: reduced elimination leading to higher systemic exposure.